Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis
HardmanJANicuCTaiCHarriesMMironovAPurbaTSet al
The general obesity population in TRIUMPH-1 showed dysesthesia at a lower rate than TRIUMPH-4's 20.9%, which is consistent with differences between the two populations (TRIUMPH-4's cohort was older and had more comorbidities)
Trademark Information: BetaPower is a registered trademark of Danisco USA, Inc., Bio-Enhanced Na-RALA is a registered trademark of GeroNova, Inc., BIOSINT is a trademark of Sigma-Tau HealthScience USA., Setria is a registered trademark of Kyowa Hakko Bio Co., Ltd
10.1111/obr.12465 7 BuseJ
Thus, QMP provides both favorable FcRn binding properties and a stable albumin protein, irrespective of the presence of L585